Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma

Objective: To investigate intravitreal aflibercept (IVA) injection as an adjunctive treatment to trabeculectomy with mitomycin C (TMC) and panretinal photocoagulation (PRP) for neovascular glaucoma (NVG). Materials and Methods: PRP and IVA (2 mg/0.05 ml) injection were given, and TMC was performed w...

Full description

Saved in:
Bibliographic Details
Main Authors: Naris Kitnarong, Janyawassamon Kittipiriyakul, Anuwat Jiravarnsirikul
Other Authors: Siriraj Hospital
Format: Article
Published: 2022
Subjects:
Online Access:https://repository.li.mahidol.ac.th/handle/123456789/75110
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Mahidol University
id th-mahidol.75110
record_format dspace
spelling th-mahidol.751102022-08-04T11:39:35Z Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma Naris Kitnarong Janyawassamon Kittipiriyakul Anuwat Jiravarnsirikul Siriraj Hospital Medicine Objective: To investigate intravitreal aflibercept (IVA) injection as an adjunctive treatment to trabeculectomy with mitomycin C (TMC) and panretinal photocoagulation (PRP) for neovascular glaucoma (NVG). Materials and Methods: PRP and IVA (2 mg/0.05 ml) injection were given, and TMC was performed within 2 weeks after IVA. Additional PRP, laser suture lysis, subconjunctival 5-fluorouracil injection, and bleb needling were performed after TMC if indicated. Best corrected visual acuity (BCVA), intraocular pressure (IOP), surgical complications, and number of anti-glaucoma medications were collected. Results: Five eyes from 5 consecutive patients were included. Two eyes had proliferative diabetic retinopathy (PDR), 2 central retinal vein occlusion, and 1 ocular ischemic syndrome (OIS) (mean initial IOP: 46.8±6.8 mmHg). NVI regression occurred in one eye after PRP alone, and in one eye after PRP and IVA resulting in a good IOP control with topical medical therapy. The other 3 underwent TMC. The preoperative IOP was 34 (OIS), 54 (PDR), and 50 (PDR) mmHg. The 3-month postoperative IOP decreased to 8, 8, and 4 mmHg, respectively, and to 21, 10, and 6 mmHg, respectively, at the last visit. Only the one OIS eye required postoperative topical IOP-lowering medications. Final BCVA was improved, unchanged, and decreased in 2, 2, and 1 eye, respectively. No intraoperative/postoperative complications or NVI recurrence were observed (mean follow-up: 10.7 months). Conclusion: Intravitreal aflibercept was shown to be a potentially effective additional treatment to PRP and TMC in patients with NVG. 2022-08-04T04:39:35Z 2022-08-04T04:39:35Z 2022-01-01 Article Siriraj Medical Journal. Vol.74, No.1 (2022), 27-33 10.33192/SMJ.2022.4 22288082 2-s2.0-85123535944 https://repository.li.mahidol.ac.th/handle/123456789/75110 Mahidol University SCOPUS https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85123535944&origin=inward
institution Mahidol University
building Mahidol University Library
continent Asia
country Thailand
Thailand
content_provider Mahidol University Library
collection Mahidol University Institutional Repository
topic Medicine
spellingShingle Medicine
Naris Kitnarong
Janyawassamon Kittipiriyakul
Anuwat Jiravarnsirikul
Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma
description Objective: To investigate intravitreal aflibercept (IVA) injection as an adjunctive treatment to trabeculectomy with mitomycin C (TMC) and panretinal photocoagulation (PRP) for neovascular glaucoma (NVG). Materials and Methods: PRP and IVA (2 mg/0.05 ml) injection were given, and TMC was performed within 2 weeks after IVA. Additional PRP, laser suture lysis, subconjunctival 5-fluorouracil injection, and bleb needling were performed after TMC if indicated. Best corrected visual acuity (BCVA), intraocular pressure (IOP), surgical complications, and number of anti-glaucoma medications were collected. Results: Five eyes from 5 consecutive patients were included. Two eyes had proliferative diabetic retinopathy (PDR), 2 central retinal vein occlusion, and 1 ocular ischemic syndrome (OIS) (mean initial IOP: 46.8±6.8 mmHg). NVI regression occurred in one eye after PRP alone, and in one eye after PRP and IVA resulting in a good IOP control with topical medical therapy. The other 3 underwent TMC. The preoperative IOP was 34 (OIS), 54 (PDR), and 50 (PDR) mmHg. The 3-month postoperative IOP decreased to 8, 8, and 4 mmHg, respectively, and to 21, 10, and 6 mmHg, respectively, at the last visit. Only the one OIS eye required postoperative topical IOP-lowering medications. Final BCVA was improved, unchanged, and decreased in 2, 2, and 1 eye, respectively. No intraoperative/postoperative complications or NVI recurrence were observed (mean follow-up: 10.7 months). Conclusion: Intravitreal aflibercept was shown to be a potentially effective additional treatment to PRP and TMC in patients with NVG.
author2 Siriraj Hospital
author_facet Siriraj Hospital
Naris Kitnarong
Janyawassamon Kittipiriyakul
Anuwat Jiravarnsirikul
format Article
author Naris Kitnarong
Janyawassamon Kittipiriyakul
Anuwat Jiravarnsirikul
author_sort Naris Kitnarong
title Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma
title_short Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma
title_full Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma
title_fullStr Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma
title_full_unstemmed Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma
title_sort aflibercept as adjunctive treatment for filtration surgery in neovascular glaucoma
publishDate 2022
url https://repository.li.mahidol.ac.th/handle/123456789/75110
_version_ 1763498126038007808